Oops, you're using an old version of your browser so some of the features on this page may not be displaying properly.

MINIMAL Requirements: Google Chrome 24+Mozilla Firefox 20+Internet Explorer 11Opera 15–18Apple Safari 7SeaMonkey 2.15-2.23

Poster Display session 2

5134 - Early prediction of the platinum-resistant relapse risk using the CA125 modeled kinetic parameter KELIM: a pooled analysis of AGO-OVAR 7 & 9; ICON 7 (AGO/GINECO/ MRC CTU/GCIG trials).


29 Sep 2019


Poster Display session 2




Annals of Oncology (2019) 30 (suppl_5): v403-v434. 10.1093/annonc/mdz250


O. COLOMBAN1, M. TOD2, A. Leary3, I.L. Ray-Coquard4, A. Lortholary5, A. Hardy-Bessard6, J. Pfisterer7, A. du Bois8, C. Kurzeder9, A. Burges10, J. Peron11, G. Freyer12, B. You13

Author affiliations

  • 1 Emr3738, Ciblage Thérapeutique En Oncologie, Faculté De Médecine Et De Maïeutique Lyon-sud Charles Mérieux, Université Claude Bernard Lyon 1, 69921 - OULLINS/FR
  • 2 Emr 3738, Université Claude Bernard Lyon 1, 6904 - LYON/FR
  • 3 Medical Oncology, Institut Gustave Roussy; GINECO-GINEGEPS, 94800 - Villejuif/FR
  • 4 Medical Oncology, Centre Léon Bérard; GINECO, 69008 - Lyon/FR
  • 5 Oncologie Médicale, Hôpital Privé du Confluent; GINECO S.A.S., 44277 - Nantes Cédex/FR
  • 6 Medical Oncology, Clinique Armoricaine de Radiologie; GINECO, 22000 - St. Brieuc/FR
  • 7 Gynecology-obstetrics, Womens Cancer Center, 24103 - Kiel/DE
  • 8 Gynecology-obstetrics, Kliniken Essen Mitte Evang. Huyssens-Stiftung, 45136 - Essen/DE
  • 9 Gynecology-oncology, University Hospital Basel, 4031 Basel, Switzerland, Basel/CH
  • 10 Gynecology-obstetrics, 11. University of Munich, Campus Großhadern, Munich/DE
  • 11 Medical Oncology Department, Institut de Cancérologie des Hospices Civils de Lyon, Lyon/FR
  • 12 Medical Oncology, Centre Hospitalier Lyon Sud, Institut de Cancérologie des Hospices Civils de Lyon, Lyon, France; GINECO, 69495 - Pierre Bénite/FR
  • 13 Service D'oncologie Médicale, CITOHL, Centre Hospitalo-Universitaire Lyon-Sud, Institut de Cancérologie des Hospices Civils de Lyon (IC-HCL), Pierre-Bénite; GINECO-GINEGEPS, 69310 - Pierre Bénite/FR


Login to access the resources on OncologyPRO.

If you do not have an ESMO account, please create one for free.

Abstract 5134


Platinum-resistant relapse after 1st line treatment (platinum-free interval < 6 months) is a very detrimental event for patient survival. The modeled CA125 elimination parameter KELIM calculated during the first 100 chemotherapy days is a predictive factor of PFS/OS in 1st line treatment (Colomban et al. Clin Cancer Res 2019). KELIM was associated with the risk of subsequent platinum-resistant relapse (PtRR) in neoadjuvant setting (Robelin et al. Proc ASCO 2019). The objective was to validate the predictive value of KELIM in 1st line treatment (with primary debulking surgery) on the data of 3 large phase III trials, and to integrate it in a Platinum-Resistant Recurrence Score.


Data from AGO-OVAR 9 (carboplatin-paclitaxel (CP) +/- gemcitabine); AGO-OVAR 7 (CP +/- topotecan); and ICON 7 trials (CP +/- bevacizumab) were analyzed. The predictive value of individual modeled KELIM regarding the risk of subsequent PtRR was assessed with other prognostic factors (stages; histological subtypes; grades; arms; GCIG CA125 criteria; Oza groups in ICON 7) using multivariate ROC curve & logistic models.


Among assessable 2868 patients, 208 patients experienced subsequent PtRR (7.2%). Median KELIM (days-1) gradually increased with the subsequent PFIs: <6 months, 0.043; 6-12 months, 0.052; > 12 months, 0.065 (P < 0.05). Using multivariate logistic models, 3 covariates were significantly associated with PtRR risk: continuous KELIM (OR, 0.17 95% CI [0.11-0.25]; disease stage III (OR, 7.51 [3.70-18.02]); or stage IV (OR, 19.28 [9.06-47.80]); or Oza high risk group in ICON7 (OR 2.35 [1.79-3.10]). They were integrated in a Platinum-Resistant Recurrence Score meant to predict the individual risk of subsequent PtRR (i.e. risk calculated at 60% if KELIM = 0.2 and stage III).


Modeled KELIM, easily calculable online with three CA125 values observed during the first 100 adjuvant chemotherapy days (http://www.biomarker-kinetics.org/), is related to primary chemoresistance and survival. It has been integrated in a Platinum Resistant Recurrence Score that predicts the individual risk of PtRR in 1st line setting.

Clinical trial identification

Editorial acknowledgement

No assistance

Legal entity responsible for the study



Has not received any funding.


All authors have declared no conflicts of interest.

This site uses cookies. Some of these cookies are essential, while others help us improve your experience by providing insights into how the site is being used.

For more detailed information on the cookies we use, please check our Privacy Policy.

Customise settings
  • Necessary cookies enable core functionality. The website cannot function properly without these cookies, and you can only disable them by changing your browser preferences.